ABS Compliance for International MTAs

When a material transfer agreement (MTA) moves a biological sample — a plant specimen, a soil microbe, a cell line, an animal tissue sample — across an international border, it can trigger a second, largely separate compliance obligation that has nothing to do with the MTA’s usual concerns of liability, publication rights, or field-of-use. Under the Nagoya Protocol on Access and Benefit-Sharing (ABS), a supplementary agreement to the Convention on Biological Diversity (CBD), a country that is the origin of a genetic resource can condition access to it on prior consent and a binding commitment to share the benefits of using it. For a technology transfer office (TTO) or sponsored-programs office negotiating an international MTA, ABS compliance is not a side issue — it determines what the MTA is legally allowed to say, and in some cases whether it can be signed at all.

This guide covers how ABS obligations attach to an MTA specifically: what triggers them, what an MTA needs to contain to satisfy them, how the European Union’s implementing regulation adds a due-diligence layer on top of the Protocol itself, and the institutional workflow a TTO uses to catch ABS exposure before a shipment goes out the door.

ABS in one paragraph: access, benefit-sharing, compliance

The Nagoya Protocol was adopted in Nagoya, Japan in October 2010 and entered into force on 12 October 2014, once 50 countries had ratified it. It operationalizes CBD Article 15, which recognizes that states have sovereign rights over the genetic resources within their territory and can set conditions on access to them. The Protocol is organized around three linked obligations, often shorthanded as the “ABCs of ABS”:

Access — a party country can require Prior Informed Consent (PIC) from its designated national competent authority before a genetic resource within its jurisdiction can be collected or exported for research or commercial use.
Benefit-sharing — access is conditioned on Mutually Agreed Terms (MAT), a negotiated agreement between the provider and the user that specifies how benefits from using the resource — monetary (royalties, milestone payments, licensing fees) or non-monetary (co-authorship, capacity building, technology sharing, access to research results) — will be shared with the providing country or community.
Compliance — each party is expected to implement measures ensuring that genetic resources used within its jurisdiction were accessed in accordance with the provider country’s PIC/MAT requirements, and to designate checkpoints that monitor utilization.

Where MAT exists, its terms are not usually written into a separate freestanding contract — they get written into whatever instrument actually moves the material or governs its use. For a biological sample crossing an institutional or national border, that instrument is the MTA. This is the direct link between ABS compliance and MTA drafting: PIC is a permit-level determination made before an MTA is signed, and MAT is the substance that gets built into the MTA’s benefit-sharing clause.

What triggers ABS obligations for a given MTA

Not every international MTA carries ABS exposure. The obligation turns on what is being transferred, where it originated, and what it will be used for:

The material is a genetic resource, or associated traditional knowledge. The Nagoya Protocol’s scope covers genetic resources (broadly, material of plant, animal, microbial, or other origin containing functional units of heredity, and their genetic/biochemical composition) and traditional knowledge associated with those resources held by indigenous and local communities.
It originates in, and is accessed on or after, a Nagoya Party’s implementation date. The obligation is anchored to the provider country’s ABS legislation, not to whether the receiving institution’s own country has ratified the Protocol. The United States has never ratified the CBD or the Nagoya Protocol, but a US university receiving a sample from a Party country is still bound by that provider country’s PIC/MAT requirements — the compliance obligation travels with the material, not with the recipient’s jurisdiction.
The intended use is “utilization.” Nagoya’s compliance regime is triggered by research and development on the genetic or biochemical composition of the resource, not by mere possession, transport, or use as a reference specimen.

Two categories are commonly excluded or handled under a separate regime, and both are worth checking before assuming Nagoya applies:

Human genetic resources are explicitly outside the CBD/Nagoya framework, which governs non-human genetic resources; human-subjects material is instead governed by informed-consent and IRB/ethics requirements, which follow their own path in an MTA or data-use agreement.
Plant genetic resources for food and agriculture listed under the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) are covered by that treaty’s own Standard Material Transfer Agreement (SMTA) instead of Nagoya’s general ABS regime — the ITPGRFA operates as the more specific instrument (lex specialis) for the crop genebank material it covers.

Building ABS terms into the MTA itself

Where ABS applies, the MTA is where PIC and MAT actually become operational. A compliance-ready international MTA involving a genetic resource typically needs to address, beyond the standard MTA clauses already covered in CASRAI’s general MTA process guide:

Provenance and permit reference — the country of origin, the PIC permit or equivalent authorization reference number, and, where one has been issued, the Internationally Recognized Certificate of Compliance (IRCC) number registered with the ABS Clearing House (the CBD Secretariat’s public online platform where Parties publish national ABS legislation, competent authority contacts, and issued permits).
Benefit-sharing clause — the negotiated MAT terms: what monetary and/or non-monetary benefits flow back to the provider, and on what trigger (execution, a commercialization milestone, publication).
Scope-of-use restriction — utilization is typically authorized only for the specific research purpose disclosed at the time PIC was obtained; a materially different use (e.g., moving from academic characterization to commercial product development) usually requires renegotiating MAT, not just amending the MTA privately between the two immediate parties.
Third-party transfer restriction — because ABS obligations run with the resource, an MTA should prohibit onward transfer to a third party without either the provider’s consent or a flow-down clause binding the recipient to the same PIC/MAT terms.
Derivatives and sequence data — whether genetic sequence data derived from the material (and deposited to an open-access database) is treated as within scope of the original PIC/MAT is a genuinely unsettled and actively debated question internationally; an MTA should state the parties’ agreed position rather than leave it silent.
Compliance representation — a clause in which the provider represents that PIC was properly obtained and MAT properly negotiated, giving the recipient institution a documented basis for its own due-diligence file.

The EU’s due-diligence overlay: Regulation (EU) No 511/2014

Institutions receiving or sending material through the EU face an additional layer beyond the Protocol itself. The EU adopted Regulation (EU) No 511/2014 on 16 April 2014 to implement Nagoya Protocol compliance measures across the Union. It doesn’t replace PIC/MAT — it adds a due-diligence obligation on users of genetic resources within the EU, requiring them to:

Seek, keep, and transfer to subsequent users the information needed to demonstrate legal access (permit or IRCC reference, PIC and MAT documentation, source and date of access);
Submit a due-diligence declaration at defined “checkpoints” — when receiving funds for research involving utilization of genetic resources, and at the stage of final product development, prior to market approval or commercialization; and
Retain due-diligence records for a defined period after utilization ends (commonly cited as 20 years under the regulation’s implementing rules) in case of a compliance check.

For a TTO negotiating an inbound or outbound MTA that touches the EU on either side, the due-diligence declaration obligation is a separate, EU-specific administrative step layered on top of whatever PIC/MAT terms are already written into the MTA — it doesn’t change what the MTA needs to say, but it does add a filing requirement that has its own deadline, independent of the MTA’s execution date.

Institutional workflow: catching ABS exposure before the MTA is signed

Because ABS compliance failures surface downstream — at publication, at licensing, at a funder’s compliance check — the practical discipline is to screen for it at MTA intake, before material moves. A workable checklist for a TTO or sponsored-programs office:

Identify the resource type. Is it a genetic resource (or associated traditional knowledge) within Nagoya’s scope, or excluded (human-subjects material, ITPGRFA-covered crop genetic resources, synthetic/non-biological reagents)?
Identify the country of origin and its ABS status. Is it a Nagoya Party with an active domestic ABS regime? The ABS Clearing House is the authoritative source for a country’s designated national competent authority and its specific access requirements — requirements vary significantly by country and are not standardized by the Protocol itself.
Confirm PIC exists before drafting MAT/MTA terms. An MTA negotiated without confirmed PIC risks being unenforceable against the provider’s own domestic ABS law, regardless of what the two institutions privately agree.
Draft or review the MTA’s ABS-specific clauses against the list above, coordinating with whoever holds the PIC permit/IRCC documentation.
Flag EU checkpoint obligations separately if either party is EU-based, since the due-diligence declaration is filed independently of the MTA’s execution.
Retain the full due-diligence file — permit, PIC correspondence, MAT/MTA, IRCC reference — for the life of the utilization and beyond, since compliance checks can occur well after a project concludes.

What non-compliance actually risks

An MTA signed without valid PIC/MAT exposes an institution to several distinct risks: the provider country’s competent authority can revoke access or refuse future permits to the institution; a funder or journal that requires ABS compliance documentation as a condition of funding or publication can withhold or retract; and a downstream commercial partner performing its own due diligence during a licensing deal can discover the defect and use it to renegotiate or walk away. Because obligations run with the material rather than with any one signatory, the exposure doesn’t end when the original MTA’s term does — it follows the resource and its derivatives through every subsequent transfer.

How this differs from CASRAI’s existing benefit-sharing and MTA content

This guide addresses a narrower, more mechanical question than CASRAI’s Benefit-Sharing Agreement dictionary entry, which frames benefit-sharing around indigenous and local community engagement, CARE Principles-aligned practice, and co-developed community arrangements — the human, community-facing side of ABS. This guide instead covers the drafting mechanics a TTO or sponsored-programs office works through when Nagoya/CBD obligations have to be written into a specific contract instrument: what clause language an MTA needs, what the EU’s due-diligence regulation adds procedurally, and how an office screens incoming and outgoing biological material for ABS exposure before signature. The two pages are complementary, not competing: a genuine community benefit-sharing arrangement under the Nagoya framework is exactly the kind of MAT this guide describes getting written into an MTA.

Similarly, CASRAI’s general MTA process guide covers the domestic US MTA process — UBMTA, the NIH Simple Letter Agreement, and export-control overlays — but does not address ABS/Nagoya compliance at all. This guide fills that specific gap for MTAs that carry an international, biodiversity-origin dimension. For related agreement-type distinctions, see MTA vs. NDA and Research Collaboration Agreement vs. MTA.

Frequently asked questions

Does ABS compliance apply if my institution is in a country that hasn’t ratified the Nagoya Protocol?

Yes, if the material originates in a Party country. The obligation attaches to where and how the resource was accessed, not to the recipient institution’s own country’s ratification status. A US or other non-Party institution receiving a genetic resource from a Party country is still expected to comply with that provider country’s PIC/MAT requirements when using the material.

Is a material transfer agreement the same thing as Mutually Agreed Terms?

Not automatically. MAT is the substantive benefit-sharing agreement negotiated between provider and user under Nagoya; the MTA is the contract instrument that, for a physical material transfer, is the practical vehicle for writing those MAT terms down alongside the transfer’s other standard provisions. An MTA can exist without ABS content (most domestic MTAs do); MAT, once negotiated, needs some binding document to carry it, and for physical samples that document is usually the MTA.

Do human tissue or cell line transfers fall under Nagoya?

No. Human genetic resources are outside the CBD/Nagoya framework. Human-subjects biological material is instead governed by informed-consent, IRB/ethics review, and any applicable human-subjects data protections, which follow a separate compliance path from ABS.

What is the ABS Clearing House and why does it matter for an MTA?

It’s the CBD Secretariat’s public platform where Parties publish their national ABS legislation, designated competent authorities, and issued permits/IRCCs. It’s the authoritative first stop for confirming whether a given provider country requires PIC, what its process looks like, and for verifying a permit or IRCC number referenced in an MTA.